SEQUENCE LISTING

<110> Klaveness, Jo
Rongved, Pal
Hogset, Anders
Tolleshaug, Helge
Cuthbertson, Alan
Godal, Aslak
Hoff, Lars
Gogstad, Geir
Bryn, Klaus
Naevestad, Anne
Lovhaug, Dagfinn
Hellebust, Halldis
Solbakken, Magne

<120> Diagnostic/Therapeutic Agents

<130> NIDN-10314

<140> 10/734,730
<141> 2003-12-15

<150> 09/925,715
<151> 2001-08-10

<150> 08/959,206
<151> 1997-10-28

<150> 60/049,263
<151> 1997-06-07

<150> 60/049,264
<151> 1997-06-06

<150> 60/049,266
<151> 1997-06-07

<160> 20

<170> PatentIn version 3.1

<210> 1
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Heparin sulphate binding peptide

<400> 1

Lys Arg Lys Arg
1

<210> 2
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Fibronectin peptide

<400> 2

Trp Gln Pro Pro Arg Ala Arg Ile
1 5

<210> 3
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Lipopeptide consisting of heparin sulphate binding peptide and fibronectin peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> Dipalmitoyl-lysine

<400> 3

Lys Lys Arg Lys Arg Trp Gln Pro Pro Arg Ala Arg Ile
1 5 10

<210> 4
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic RGDC sequence

<400> 4

Arg Gly Asp Cys
1

<210> 5
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic fusion peptide comprising a PS binding component and a fibronectin peptide sequence

<400> 5

Phe Asn Phe Arg Leu Lys Ala Gly Gln Lys Ile Arg Phe Gly Gly Gly
1 5 10 15

Gly Trp Gln Pro Pro Arg Ala Ile
20

<210> 6
<211> 6

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Biotinylated endothelin-1 peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> Biotin-D-Trp

<400> 6

Trp Leu Asp Ile Ile Trp
1 5

<210> 7
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Biotinylated fibrin-antipolymerant peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> Biotin-Gly

<220>
<221> MOD_RES
<222> (10)..(10)
<223> AMIDATION

<400> 7

Gly Pro Arg Pro Pro Glu Arg His Gln Ser
1 5 10

<210> 8
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Lipopeptide

<220>
<221> MOD_RES
<222> (5)..(5)
<223> Biotinylated-lys

<220>
<221> MOD_RES
<222> (1)..(1)
<223> Dipalmitoyl-lysine

<400> 8

Lys Trp Lys Lys Lys Gly
1 5

<210> 9
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Biotinylated synthetic oligonucleotide

<220>
<221> misc_feature
<222> (1)..(1)
<223> Biotinylated

<400> 9
gaaaggtagt ggggtcgtgt gccgg 25

<210> 10
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Biotinylated synthetic oligonucleotide

<220>
<221> misc_feature
<222> (1)..(1)
<223> Biotinylated

<400> 10
ggcgctgatg atgttgttga ttctt 25

<210> 11
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Descriptionof Artificial Sequence: Lipopeptide containing the RGD sequence and a fluorescein reporter group

<220>
<221> MOD_RES
<222> (1)..(1)
<223> Dipalmitoyl-lys

<220>
<221> MOD_RES
<222> (4)..(4)
<223> Acetyl-RGD-K-fluorescein side chain

<400> 11

Lys Lys Lys Lys Gly
1 5

<210> 12
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic endothelial cell binding lipopeptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> 2-n-hexadecylstearyl-lysine

<220>
<221> MOD_RES
<222> (18)..(18)
<223> AMIDATION

<400> 12

Lys Leu Ala Leu Lys Leu Ala Leu Lys Ala Leu Lys Ala Ala Leu Lys
1 5 10 15

Leu Ala

<210> 13
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Thiol functionalised lipid molecule

<220>
<221> MOD_RES
<222> (1)..(1)
<223> Dipalmitoyl-lysine

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Acp

<400> 13

Lys Lys Lys Xaa Cys

1 5

<210> 14
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic lipopeptide functionalised with captopril

<220>
<221> MOD_RES
<222> (1)..(1)
<223> Dipalmitoyl-lysine

<220>
<221> MOD_RES
<222> (4)..(4)
<223> AMIDATION

<220>
<221> MOD_RES
<222> (4)..(4)
<223> Amide-linked via side chain to captopril

<400> 14

Lys Lys Lys Lys
1

<210> 15
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic lipopeptide functionalised with captopril

<220>
<221> MOD_RES
<222> (1)..(1)
<223> Dipalmitoyl-lysine

<220>
<221> MOD_RES
<222> (4)..(4)
<223> Acp

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Acp

<220>
<221> MOD_RES
<222> (13)..(13)
<223> AMIDATION

<400> 15

Lys Lys Lys Xaa Ile Arg Arg Val Ala Arg Pro Pro Leu
1 5 10

<210> 16
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Lipopeptide comprising an interleukin 1 receptor binding peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> Dipalmitoyl-lysine

<400> 16

Lys Gly Asp Trp Asp Gln Phe Gly Leu Trp Arg Gly Ala Ala
1 5 10

<210> 17
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Core peptide comprising dabsylated-atherosclerotic plaque binding sequence and RGDS

<220>
<221> MOD_RES
<222> (1)..(1)
<223> Dabsylated-tyrosine

<220>
<221> MOD_RES
<222> (10)..(10)
<223> Arg-Gly-Asp-Ser chain liked via NH2 group of lysine

<400> 17

Tyr Arg Ala Leu Val Asp Thr Leu Lys Lys Gly Cys
1 5 10

<210> 18
<211> 15

<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Lipopeptide with an affinity for thrombi

<220>
<221> MOD_RES
<222> (1)..(1)
<223> Dipalmitoyl-lysine

<220>
<221> MOD_RES
<222> (15)..(15)
<223> AMIDATION

<400> 18

Lys Asn Asp Gly Asp Phe Glu Glu Ile Pro Glu Glu Tyr Leu Gln
1 5 10 15

<210> 19
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Lipopeptide functionalised with atenolol

<220>
<221> MOD_RES
<222> (1)..(1)
<223> Dipalmitoyl-lysine

<220>
<221> MOD_RES
<222> (4)..(4)
<223> AMIDATION

<220>
<221> MOD_RES
<222> (4)..(4)
<223> Lysine with side chain linked via amide bond to atenolol

<400> 19

Lys Lys Lys Lys
1

<210> 20
<211> 4
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Lipopeptide containing chlorambucil

<220>
<221> MOD_RES
<222> (1)..(1)
<223> Dipalmitoyl-lysine

<220>
<221> MOD_RES
<222> (4)..(4)
<223> Lysine with side chain linked via amide bond chlorambucil

<220>
<221> MOD_RES
<222> (4)..(4)
<223> AMIDATION

<400> 20

Lys Lys Lys Lys
1